Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P32754

UPID:
HPPD_HUMAN

ALTERNATIVE NAMES:
4-hydroxyphenylpyruvic acid oxidase

ALTERNATIVE UPACC:
P32754; A8K461; B3KQ63; Q13234

BACKGROUND:
4-Hydroxyphenylpyruvate dioxygenase, identified by the protein accession number P32754, is pivotal in the metabolic pathway of tyrosine, facilitating its breakdown. The enzyme's alternative name, 4-hydroxyphenylpyruvic acid oxidase, highlights its specific action in the conversion process crucial for tyrosine catabolism.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting this enzyme lead to metabolic diseases such as Tyrosinemia 3 and Hawkinsinuria, underscoring its significance in human health. The exploration of 4-hydroxyphenylpyruvate dioxygenase's function and its genetic variants offers a promising avenue for developing targeted treatments for these inherited metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.